Nykode Therapeutics, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, has entered into a strategic manufacturing partnership with Richter-Helm BioLogics to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio.
“We are excited about the strategic manufacturing partnership with Richter-Helm BioLogics. As a leading manufacturer of DNA vaccines, they will provide the long-term expertise and capacity needed to support our ambitious growth and pipeline development,” said Mette Husbyn, chief technology officer at Nykode Therapeutics.
“We are thrilled to collaborate with Nykode Therapeutics and to support the development of their leading DNA vaccine platform. After 30 years of manufacturing plasmid DNA, we have gained an unparalleled amount of first-hand plasmid DNA process knowledge and experience working with regulatory agencies to ensure cGMP compliance for clinical trials and late-stage product candidates,” said Dr.Kai Pohlmeyer, managing director of Richter-Helm BioLogics.
Manufacturing is a strategic focus area for Nykode and its license partners. Under the partnership agreement with Richter-Helm BioLogics, Nykode will have the option to tech transfer the proprietary manufacturing processes to its partners, if requested.